Localization of ADAMTS 13 to the stellate cells of human liver

Third Department of Internal Medicine, Department of Anatomy, Nara Medical University, 840 Shijo-cho, Kashihara City, Nara, 634-8522, Japan.
Blood (Impact Factor: 9.78). 09/2005; 106(3):922-4. DOI: 10.1182/blood-2005-01-0152
Source: PubMed

ABSTRACT Although the chromosomal localization (9q34) of the gene encoding the human form of ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13) and its exclusive expression in the liver have been established, the cells that produce this enzyme are yet to be determined. We investigated the expression of ADAMTS13 mRNA and protein in fresh frozen specimens obtained during liver biopsies of 8 patients with liver diseases. In situ hybridizations to localize ADAMTS13 mRNA showed positive signals exclusively in perisinusoidal cells with irregularly elongated dendritic processes extending between hepatocytes. Furthermore, ADAMTS13 was detected immunohistochemically in perisinusoidal cells, whereas no staining was observed in hepatocytes. The positive cells varied in shape from unipolar to dendritic with irregularly elongated cytoplasmic processes, features common to hepatic stellate cells (HSCs). Double-labeling experiments revealed that the ADAMTS13-positive cells also expressed alpha-smooth muscle actin, confirming that these cells were activated HSCs. These results suggest that HSCs may be major cells producing ADAMTS13 in human liver.

Download full-text


Available from: Akio Wanaka, Jun 21, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ADAMTS13 is a specific von Willebrand factor-cleaving protease. Severe deficiency of ADAMTS13 is the main cause of thrombotic thrombocytopenic purpura. ADAMTS13 is mainly synthesized and released from hepatic stellate cells and endothelial cells, but is also expressed in other cells, including kidney podocytes. Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has a beneficial effect on atherosclerosis and also has anti-inflammatory and antithrombotic properties. A recent study indicates that ADAMTS13 reduces inflammatory plaque formation during early atherosclerosis in mice. In our study, we investigated the effects of simvastatin on inflammatory cytokines-induced ADAMTS13 expression in podocytes. A conditionally immortalized mouse podocyte cell line was utilized to study the expression of ADAMTS13 in podocytes. The influence of TNF-α, IL-4, IL-6 and simvastatin on ADAMTS13 was investigated. ADAMTS13 mRNA levels in podocytes were measured by using real-time PCR and protein levels were detected by Western blotting. Simvastatin significantly up-regulated the expression levels of ADAMTS13 mRNA and protein in podocytes. IL-6 decreased ADAMTS13 expression, and TNF-α had no significant effects on ADAMTS13 expression in podocytes. IL-4 reduced ADAMTS13 mRNA expression but not its protein level. Simvastatin was able also reversed the inhibitory effect of IL-6. We demonstrate that simvastatin increases the expression of ADAMTS13 in a dose-dependent manner in podocytes, which likely contributes to the antithrombotic property of statin. Different inflammatory cytokines have different effects on the levels of ADAMTS13 mRNA expression and protein within podocytes.
    Thrombosis Research 06/2013; 132(1). DOI:10.1016/j.thromres.2013.05.024 · 2.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cilostazol is an anti-platelet drug that reversibly inhibits phosphodiesterase III (PDE-III), which is ubiquitously expressed in platelets and various tissues. PDE-III converts cyclic adenosine monophosphate (cAMP) to 5'-AMP and up-regulates the intracellular concentration of cAMP, a potent inhibitor of platelet aggregation. Unlike other anti-platelet drugs, cilostazol is unique because patients receiving this drug do not have a significantly prolonged bleeding time, but the reasons for this difference are still unknown. In this study, we have examined how cilostazol inhibits platelet thrombus formation using anti-coagulated normal whole blood in which the platelets were labeled with a fluorescent dye in comparison with the anti-GPIIb/IIIa agent, tirofiban. We used an in vitro assay to examine mural platelet thrombus growth on a collagen surface under a high-shear rate flow in the absence of ADAMTS13 activity. These experimental conditions mimic the blood flow in patients with thrombotic thrombocytopenic purpura. Using this model, we clearly determined that cilostazol down-regulates the height of mural platelet thrombi formed on a collagen surface in a dose-dependent manner, without affecting the surface coverage. The concentration of cilostazol used in this study was relatively high (60-120 μM) compared to clinically relevant concentrations (1-3 μM), which may be due to the in vivo synergistic effects of PDE-III present in other tissues aside from platelets. Cilostazol does not affect the initial formation of platelet thrombi, but does inhibit the height of thrombi. These results showed a sharp contrast to tirofiban, and address why cilostazol does not significantly prolong bleeding time, despite its strong anti-platelet activity.
    European journal of pharmacology 07/2012; 691(1-3):151-5. DOI:10.1016/j.ejphar.2012.07.001 · 2.68 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening generalized disease with pathological conditions termed thrombotic microangiopathy (TMA). TTP is thought to predominantly affect adults and to rarely occur in children. Currently, TTP is defined by a severe deficiency in the activity of ADAMTS13, a metalloprotease that specifically cleaves unusually large von Willebrand factor multimers under high shear stress. Genetic mutations in and acquired autoantibodies to ADAMTS13 cause congenital TTP (termed Upshaw-Schulman syndrome [USS]) and acquired TTP, respectively. Because of very few overt clinical signs for TTP, USS is often misdiagnosed as chronic idiopathic thrombocytopenic purpura or overlooked during childhood. However, in women with USS, pregnancy can induce thrombocytopenia followed by the development of TTP. Furthermore, early childhood cases of acquired idiopathic TTP have not been characterized. From 1998 to 2008, our institution at Nara Medical University functioned as a TMA referral center in Japan and collected a large dataset on 919 TMA patients (Intern Med 2010;49:7-15). This registry contains 324 patients with a severe deficiency in ADAMTS13 activity, including 41 patients with USS and 283 patients with acquired TTP. Of note, the latter population contains 17 patients who were enrolled as children (≤ 15years old), including 14 children with idiopathic TTP and three with connective tissue disease-associated TTP. Of the 14 patients with idiopathic TTP, five were very young children (under 2 years old). This study focused on these 58 patients (41 USS and 17 acquired TTP) who were diagnosed with a severe deficiency in ADAMTS13 activity during childhood, causing a paradigm shift in our concept of TTP.
    La Presse Médicale 03/2012; 41(3 Pt 2):e137-55. DOI:10.1016/j.lpm.2011.10.027 · 1.17 Impact Factor